Open Access

The ‘timely’ development of Rexin-G: First targeted injectable gene vector (Review)

  • Authors:
    • Erlinda M. Gordon
    • Frederick L. Hall
  • View Affiliations

  • Published online on: August 1, 2009     https://doi.org/10.3892/ijo_00000332
  • Pages: 229-238
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

In an age where we can i) know precisely where a misplaced automobile resides by its global positioning, ii) send mechanistic probes to Mars with pinpoint accuracy, iii) calculate exactly how many mutations are required to create (i.e., to transform) a cancer cell, and iv) determine how many fewer genes it takes to develop a human being than it does a rice plant, it is difficult to fathom the previously unanswered question: ‘Whatever happened to the promise and potential of cancer gene therapy?’ This review answers that question with a resounding clinical dénouement. In addition, it provides a ‘Cooks tour’ of applied molecular genetics and nanotechnology as these fields relate to the development of Rexin-G the world's first tumor-targeted genetic medicine to be fully validated in the clinic. The commentary will expose certain fallacies and ideologies that have retarded the progress of cancer gene therapy as it advances our instruments and understanding of the finespun fabric of our nature.

Related Articles

Journal Cover

August 2009
Volume 35 Issue 2

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Gordon, E.M., & Gordon, E.M. (2009). The ‘timely’ development of Rexin-G: First targeted injectable gene vector (Review). International Journal of Oncology, 35, 229-238. https://doi.org/10.3892/ijo_00000332
MLA
Gordon, E. M., Hall, F. L."The ‘timely’ development of Rexin-G: First targeted injectable gene vector (Review)". International Journal of Oncology 35.2 (2009): 229-238.
Chicago
Gordon, E. M., Hall, F. L."The ‘timely’ development of Rexin-G: First targeted injectable gene vector (Review)". International Journal of Oncology 35, no. 2 (2009): 229-238. https://doi.org/10.3892/ijo_00000332